290 related articles for article (PubMed ID: 31616406)
1. Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases.
Weißenberg SY; Szelinski F; Schrezenmeier E; Stefanski AL; Wiedemann A; Rincon-Arevalo H; Welle A; Jungmann A; Nordström K; Walter J; Imgenberg-Kreuz J; Nordmark G; Rönnblom L; Bachali P; Catalina MD; Grammer AC; Lipsky PE; Lino AC; Dörner T
Front Immunol; 2019; 10():2136. PubMed ID: 31616406
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus.
Dörner T; Szelinski F; Lino AC; Lipsky PE
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32675278
[TBL] [Abstract][Full Text] [Related]
3. Toll-Like Receptor Signaling Drives Btk-Mediated Autoimmune Disease.
Rip J; de Bruijn MJW; Appelman MK; Pal Singh S; Hendriks RW; Corneth OBJ
Front Immunol; 2019; 10():95. PubMed ID: 30761150
[TBL] [Abstract][Full Text] [Related]
4. Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B Cell Receptor Signaling and Promotes Survival of Human Lupus B Cells.
Fleischer SJ; Daridon C; Fleischer V; Lipsky PE; Dörner T
Arthritis Rheumatol; 2016 May; 68(5):1210-21. PubMed ID: 26713408
[TBL] [Abstract][Full Text] [Related]
5. High SYK Expression Drives Constitutive Activation of CD21
Keller B; Stumpf I; Strohmeier V; Usadel S; Verhoeyen E; Eibel H; Warnatz K
J Immunol; 2017 Jun; 198(11):4285-4292. PubMed ID: 28468967
[TBL] [Abstract][Full Text] [Related]
6. Amplification of Toll-like receptor-mediated signaling through spleen tyrosine kinase in human B-cell activation.
Iwata S; Yamaoka K; Niiro H; Nakano K; Wang SP; Akashi K; Tanaka Y
J Allergy Clin Immunol; 2012 Jun; 129(6):1594-601.e2. PubMed ID: 22541243
[TBL] [Abstract][Full Text] [Related]
7. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation.
Chen L; Juszczynski P; Takeyama K; Aguiar RC; Shipp MA
Blood; 2006 Nov; 108(10):3428-33. PubMed ID: 16888096
[TBL] [Abstract][Full Text] [Related]
8. B-cell subsets, signaling and their roles in secretion of autoantibodies.
Iwata S; Tanaka Y
Lupus; 2016 Jul; 25(8):850-6. PubMed ID: 27252261
[TBL] [Abstract][Full Text] [Related]
9. CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation.
Law CL; Sidorenko SP; Chandran KA; Zhao Z; Shen SH; Fischer EH; Clark EA
J Exp Med; 1996 Feb; 183(2):547-60. PubMed ID: 8627166
[TBL] [Abstract][Full Text] [Related]
10. [Involvement of Syk in pathology of systemic autoimmune disease].
Iwata S; Yamaoka K; Niiro H; Nakano K; Wang SP; Saito K; Akashi K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):56-61. PubMed ID: 22374444
[TBL] [Abstract][Full Text] [Related]
11. The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.
Crofford LJ; Nyhoff LE; Sheehan JH; Kendall PL
Expert Rev Clin Immunol; 2016 Jul; 12(7):763-73. PubMed ID: 26864273
[TBL] [Abstract][Full Text] [Related]
12. Activation of NF-κB in B cell receptor signaling through Bruton's tyrosine kinase-dependent phosphorylation of IκB-α.
Pontoriero M; Fiume G; Vecchio E; de Laurentiis A; Albano F; Iaccino E; Mimmi S; Pisano A; Agosti V; Giovannone E; Altobelli A; Caiazza C; Mallardo M; Scala G; Quinto I
J Mol Med (Berl); 2019 May; 97(5):675-690. PubMed ID: 30887112
[TBL] [Abstract][Full Text] [Related]
13. Decreased BAFF Receptor Expression and Unaltered B Cell Receptor Signaling in Circulating B Cells from Primary Sjögren's Syndrome Patients at Diagnosis.
Neys SFH; Verstappen GM; Bootsma H; Kroese FGM; Hendriks RW; Corneth OBJ
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563492
[TBL] [Abstract][Full Text] [Related]
14. Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1.
Maeda A; Scharenberg AM; Tsukada S; Bolen JB; Kinet JP; Kurosaki T
Oncogene; 1999 Apr; 18(14):2291-7. PubMed ID: 10327049
[TBL] [Abstract][Full Text] [Related]
15. Expression of B cell receptor-associated signaling molecules in human lupus.
Huck S; Le Corre R; Youinou P; Zouali M
Autoimmunity; 2001 May; 33(3):213-24. PubMed ID: 11683380
[TBL] [Abstract][Full Text] [Related]
16. Altered recruitment of Lyn, Syk and ZAP-70 into lipid rafts of activated B cells in Systemic Lupus Erythematosus.
Vásquez A; Baena A; González LA; Restrepo M; Muñoz CH; Vanegas-García A; Ortiz-Reyes B; Abdoel N; Rojas M; García LF; Vásquez G
Cell Signal; 2019 Jun; 58():9-19. PubMed ID: 30840855
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Haselmayer P; Camps M; Liu-Bujalski L; Nguyen N; Morandi F; Head J; O'Mahony A; Zimmerli SC; Bruns L; Bender AT; Schroeder P; Grenningloh R
J Immunol; 2019 May; 202(10):2888-2906. PubMed ID: 30988116
[TBL] [Abstract][Full Text] [Related]
18. [The importance of B cell-T cell interaction in autoimmune diseases].
Iwata S; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(5):398-402. PubMed ID: 26725861
[TBL] [Abstract][Full Text] [Related]
19. Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus.
Iwata S; Yamaoka K; Niiro H; Jabbarzadeh-Tabrizi S; Wang SP; Kondo M; Yoshikawa M; Akashi K; Tanaka Y
Lupus; 2015 Jun; 24(7):695-704. PubMed ID: 25432781
[TBL] [Abstract][Full Text] [Related]
20. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
